Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details)

v3.23.2
Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details)
Jun. 30, 2023
USD ($)
Dec. 19, 2022
USD ($)
Dec. 19, 2022
GBP (£)
Revenue      
Amount of remaining deferred income under the collaboration that had not been recognized as revenue $ 318,107,000    
GSK Collaboration And License Agreement      
Revenue      
Aggregate transaction price of the contract modification   $ 6,500,000  
Amount of remaining deferred income under the collaboration that had not been recognized as revenue $ 0    
Payment by GSK due to termination of collaboration | £     £ 5,000,000